AIAhmet Icigen

Ahmet Icigen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmet Icigen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sindirim Sistemi Hastalıkları

    by Aynur Şimşek, Akın Koçhan, Pelin Fatoş Polat Dinçer, Ömer Faruk Katanalp, Almina Güneş, Ahmet İçIgen

  • Open Access

    Veteriner Reçete-Büyük Hayvan İç Hastalıkları

    by Şükrü Değirmençay, Reyhane Bayat, Merve İdEr, Alper Ertürk, Murat Kaan Durgut, Emre Eren, Muhammed Zeyd Işık, Tahir Selçuk Yavuz, Sezai Arslan, Cenk Er, et al.

  • Open Access

    The Effects of Combination of Marbofloxacin and Ceftiofur on Serum Biochemistry in Lambs with Respiratory System Infection

    by Rahmi Canbar, Ahmet İçIgen

    In this study, the aim was to determine the effect of combination of marbofloxacin and ceftiofur on serum biochemical parameters in lambs with clinical respiratory system infection. The study included 10 Merino lambs showing symptoms of respiratory system infection in a commercial farm. Blood samples were taken from the animals before drug administration (hour 0) and 24, 48, 72, 96, and 120 hours after the first simultaneous combined drug administration (marbofloxacin 2 mg/kg, IM, once a day + ceftiofur 1 mg/kg, IM, once a day; 5 days). Serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine levels were measured in the autoanalyzer from the serum obtained from the samples taken, and the clinical symptoms of the animals were monitored daily. At the final sampling time (120 hours), AST, ALT, and BUN levels were found to be significantly higher (P < 0.05) compared to those at the initial sampling time (hour 0). On the second day of treatment, clinical signs (runny nose, fever, cough, etc.) and feed consumption began to improve. The combined use of ceftiofur and marbofloxacin is highly effective in the treatment of severe respiratory system infection in lambs.


  • Open Access

    Feline panleukopenia-associated clinicopathological abnormalities: first evaluation of diagnostic and prognostic roles of endothelial glycocalyx degradation biomarkers

    by Amir Naseri, Merve Ider, Busra Burcu Erol, Suleyman Serhat Iyıgun, Murat Kaan Durgut, Mahmut Ok, Hatice Betul Sahin, Nuri Kaan Donmez, Ahmet Icigen, Tunahan Yavuz

    The aim of this study was to investigate the role of endothelial activation and glycocalyx degradation in the pathogenesis of feline panleukopenia (FPL) using biomarkers and to determine the diagnostic and prognostic significance of these biomarkers. Thirty cats with FPL and 10 healthy cats were enrolled. Clinical examination, blood gases, and complete blood count (CBC) were performed at enrollment. Endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA), vascular endothelial growth factor-A (VEGF-A), and syndecan-1 (Syn-1) concentrations were measured using feline specific commercial enzyme-linked immunosorbent assay (ELISA) kits to assess endothelial glycocalyx damage. Nineteen (63.3%) of the cats with FPL recovered and survived, while 11 (36.7%) died. In cats with panleukopenia, acidemia was the most important blood gas finding, while leukopenia, lymphopenia, monocytopenia, granulocytopenia, and thrombocytopenia were the most dominant CBC findings. ET-1, ADMA, VEGF-A, and Syn-1 concentrations were significantly higher in cats with panleukopenia (p < 0.01). Serum Syn-1 and ET-1 concentrations were found to be useful in predicting mortality. In conclusion, the fact that the concentrations of all endothelial glycocalyx biomarkers (ET-1, ADMA, VEGF-A, Syn-1) were higher in cats with panleukopenia compared to healthy cats suggests that endothelial glycocalyx damage occurs during panleukopenia infection. In addition, Syn-1 and ET-1 were found to be potential prognostic factors with high sensitivity and specificity.